{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:30:18Z","timestamp":1784759418241,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Finnish Hematology Society"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jbo.2025.100693","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T11:13:01Z","timestamp":1749294781000},"page":"100693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Impact of treatment delay of multiple myeloma bone disease on later myeloma-related skeletal events and outcome"],"prefix":"10.1016","volume":"53","author":[{"given":"Eskelinen","family":"Veera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niemi","family":"Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partanen","family":"Anu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangas","family":"Jaakko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.L.Kuusisto","family":"Milla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jbo.2025.100693_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.jbo.2025.100693_b0010","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jbo.2025.100693_b0015","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2019.230011","article-title":"Fractures and survival in multiple myeloma: results from a population-based study","volume":"105","author":"Thorsteinsdottir","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jbo.2025.100693_b0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2010.08141.x","article-title":"Advances in the understanding of myeloma bone disease and tumour growth","volume":"149","author":"Yaccoby","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100693_b0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cden.2007.10.003","article-title":"Dental treatment planning and management in the patient who has cancer","volume":"52","author":"Brennan","year":"2008","journal-title":"Dent. Clin. North Am."},{"issue":"3","key":"10.1016\/j.jbo.2025.100693_b0030","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Bone Working Group of the International Myeloma Working Group. Treatment of multiple myeloma-related bone disease: recommendations from the bone working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100693_b0035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12903-024-03943-1","article-title":"Oral health, dental treatment, and medication related osteonecrosis of the jaw in multiple myeloma - a longitudinal cohort study","volume":"24","author":"Olofsson","year":"2024","journal-title":"BMC Oral Health"},{"issue":"4","key":"10.1016\/j.jbo.2025.100693_b0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2011.04.004","article-title":"Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma","volume":"11","author":"Wu","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"12","key":"10.1016\/j.jbo.2025.100693_b0045","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.3390\/ijms22126208","article-title":"Myeloma bone disease: a comprehensive review","volume":"22","author":"Mukkamalla","year":"2021","journal-title":"Int. J. Mol Sci."},{"issue":"3","key":"10.1016\/j.jbo.2025.100693_b0050","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"issue":"33","key":"10.1016\/j.jbo.2025.100693_b0055","article-title":"Experience with denosumab (XGEVA\u00ae) for prevention of skeletal-related events in the 10 years after approval","volume":"7","author":"Cadieux","year":"2022","journal-title":"J Bone Oncol."},{"issue":"6","key":"10.1016\/j.jbo.2025.100693_b0060","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.3390\/ijms23063112","article-title":"Pathogenesis and treatment of myeloma-related bone disease","volume":"23","author":"Gau","year":"2022","journal-title":"Int. J. Mol Sci."},{"issue":"15","key":"10.1016\/j.jbo.2025.100693_b0065","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cells11152308","article-title":"Bone disease in multiple myeloma: biologic and clinical implications","volume":"11","author":"Bernstein","year":"2022","journal-title":"Cells."},{"issue":"2","key":"10.1016\/j.jbo.2025.100693_b0070","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","article-title":"Pathogenesis of myeloma bone disease","volume":"109","author":"Roodman","year":"2010","journal-title":"J. Cell Biochem."},{"issue":"10","key":"10.1016\/j.jbo.2025.100693_b0075","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2016.146092","article-title":"Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients","volume":"101","author":"Hinge","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jbo.2025.100693_b0080","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3390\/cancers12082113","article-title":"Multiple myeloma associated bone disease","volume":"12","author":"Rasch","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbo.2025.100693_b0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.metabol.2017.11.012","article-title":"Biology and treatment of myeloma related bone disease","volume":"80","author":"Terpos","year":"2018","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.jbo.2025.100693_b0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00774-023-01408-z","article-title":"Differences between zoledronic acid and denosumab for breast cancer treatment","volume":"41","author":"Ishikawa","year":"2023","journal-title":"J. Bone Miner. Metab."},{"issue":"9","key":"10.1016\/j.jbo.2025.100693_b0095","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100693_b0100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s13018-021-02554-8","article-title":"Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials","volume":"16","author":"Jiang","year":"2021","journal-title":"J. Orthop. Surg. Res."},{"issue":"3","key":"10.1016\/j.jbo.2025.100693_b0105","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.jbo.2025.100693_b0110","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/hematolrep16030051","article-title":"First-line combination with proteasome inhibitor-based treatment and zoledronic acid is effective in reducing later fractures in multiple myeloma irrespective of multiple myeloma bone disease at diagnosis","volume":"16","author":"Eskelinen","year":"2024","journal-title":"Hematol. Rep."},{"issue":"36","key":"10.1016\/j.jbo.2025.100693_b0120","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","article-title":"Natural history of osteonecrosis of the jaw in patients with multiple myeloma","volume":"26","author":"Badros","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.jbo.2025.100693_b0125","doi-asserted-by":"crossref","unstructured":"Orhan Sezer, Myeloma bone disease: recent advances in biology, diagnosis, and treatment, the oncologist, Volume 14, Issue 3, March 2009, Pages 276\u2013283.","DOI":"10.1634\/theoncologist.2009-0003"},{"issue":"7","key":"10.1016\/j.jbo.2025.100693_b0130","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jbo.2025.100693_b0135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.24.00171","article-title":"Incidence of medication-related osteonecrosis of the jaw in patients with b cancer during a 20-year follow-up: a population-based multicenter retrospective study","volume":"43","author":"Brunner","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jbo.2025.100693_b0140","first-page":"2305","article-title":"Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis","volume":"29","author":"Srivastava","year":"2021","journal-title":"Support. Care Cancer"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213742500034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213742500034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T11:05:16Z","timestamp":1753959916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221213742500034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":27,"alternative-id":["S221213742500034X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100693","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of treatment delay of multiple myeloma bone disease on later myeloma-related skeletal events and outcome","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100693"}}